Anti-TNF Therapy in Danish Patients With Inflammatory Bowel Diseases in Clinical Practice

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02322008

Enrollment

1035

Registered

2014-12-22

Start date

2009-09-30

Completion date

2011-03-31

Last updated

2014-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn's Disease, Inflammatory Bowel Disease, Ulcerative Colitis

Brief summary

Can genetic markers be used to predict anti-TNF response? A cohort was established to identify SNPs associated with anti-TNF therapy in patients with inflammatory bowel disease.

Interventions

BIOLOGICALinfliximab and adalimumab

In this retrospective, observational study, no interventions were undertaken by the researchers.

Study design

Observational model

CASE_ONLY

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* CD or UC, treated with anti-TNF

Exclusion criteria

* Missing data

Design outcomes

Primary

Measure	Time frame	Description
3-step scale	22 weeks	Best response within 22 weeks

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026